1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Competitor Analysis: PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors

Competitor Analysis: PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors
Product description

Parathyroid hormone/parathyroid hormone-related peptide receptor also known as parathyroid hormone 1 receptor (PTH1R) functions as a receptor for parathyroid hormone (PTH) and for parathyroid hormone-related protein (PTHrP). FORTEO (teriparatide) is recombinant human parathyroid hormone analog (1-34), marketed since 2002 for the treatment of osteoporosis and related indications where an increase of bone mass is desirable. With 2012 sales of over US$ 1 bln and the forthcoming patent expiry, teriparatide is an attractive target for biosimilar developments as well as for next generation improved PTH receptor agonist products.

The present Competitive Intelligence report about PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors provides a competitor evaluation in the field of protein- and peptide-based agonists  of the parathyroid hormone (PTH) receptor for the treatment of osteoporosis as of October 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of proteins and peptides as agonists of the parathyroid hormone (PTH) receptor. In addition, the report lists company-specific R&D pipelines of PTH receptor agonists.

Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors
Competitor Analysis: PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors

Table of Contents

• 1st Generation PTH Receptor Agonists
• Teriparatide Biosimilars
• PTH-related Proteins/Peptides
• PTH Variants
• Nasal Drug Delivery Solutions for rhPTH Receptor Agonists
• Oral Drug Delivery Solutions for rhPTH Receptor Agonists
• Transdermal Drug Delivery Solutions for rhPTH Receptor Agonists
• Corporate PTH Receptor Agonist RandD Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Rheumatoid Arthritis: KOL Insight

Rheumatoid Arthritis: KOL Insight

  • $ 8 085
  • Industry report
  • March 2016
  • by Firstword Pharma

Leading brands under threat as biosimilars and new pipeline drugs hit the market Key opinion leaders (KOLs) say Rheumatoid Arthritis (RA) treatment is in for a shakeup thanks to anti-TNF biosimilars, new ...

Next-Generation Antibody Therapies Market Forecast 2016-2026: Explore Developments and Sales Potentials for ADCs, Engineered Antibodies, ALPs, Bispecific and Biosimilar Agents

Next-Generation Antibody Therapies Market Forecast 2016-2026: Explore Developments and Sales Potentials for ADCs, Engineered Antibodies, ALPs, Bispecific and Biosimilar Agents

  • $ 2 807
  • Industry report
  • April 2016
  • by Visiongain

Report Details Next-Generation Antibody Therapies – Your 2016 Guide to Trends, R&D and Predicted Revenues Where are next-generation antibody therapies heading? Visiongain’s new report shows you potential ...

Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2016-2026: And other Rising Companies – a Market Report Assessing Developers and Producers of Those Competitor Biologics

Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2016-2026: And other Rising Companies – a Market Report Assessing Developers and Producers of Those Competitor Biologics

  • $ 2 807
  • Industry report
  • April 2016
  • by Visiongain

Report Details Biosimilar Drug Producers – Your 2016 Guide to Companies’ Activities and Prospects Who are the most important and promising biosimilar drug companies? And what are their sales potentials? ...


Download Unlimited Documents from Trusted Public Sources

Renal Disease and Diabetes Statistics in China - Forecast

  • June 2016
    3 pages
  • Renal Disease  

    Diabetes  

    Biosimilar  

  • China  

    Asia  

View report >

Global Biosimilar Statistics

  • June 2016
    30 pages
  • Biosimilar  

    Therapy  

    Insulin  

  • United States  

    Austria  

    Europe  

View report >

Biopharmaceutical Industry - Forecast

  • May 2016
    3 pages
  • Biopharmaceutic...  

    Biologic Medici...  

  • China  

    Japan  

    United States  

View report >

Related Market Segments :

Biosimilar
Hormone

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.